Quote:What are the assumed MOAs for LL in AD
I dont know anything. I can only post an ai analysis of this study I recently looked at. Dont go forward if ai is unbearable. Plus I don't know if the analysis is accurate. I'm open to hearing its all possibly wrong.
Nutrient-sensing and mTORC1 regulation in neuronal homeostasis: from metabolic signaling to neurodegeneration
https://sciexplor.com/exo/articles/EXO.2026.0009
Snips:
"1. The Core Scientific Discovery: The Inflammatory-Metabolic Jam
Prof. David C. Rubinsztein’s research establishes that chronic neurodegenerative diseases share a toxic hallmark: mTORC1 is chronically hyper-activated.
The Autophagy Failure:
When mTORC1 is locked in the "on" position, it paralyzes autophagy. Because neurons cannot divide to dilute trash, this autophagy failure causes a massive accumulation of toxic, misfolded proteins (like amyloid-beta plaques and tau tangles) that eventually kill the brain cells.
The CCR5 Gateway: The study highlights that inflammatory signaling through CCR5 is a primary driver of this pathological mTORC1 overactivation. Neuro-inflammation acts as a continuous accelerator, jamming the metabolic switch open and trapping the neuron in a state of self-destruction.
2. Direct Implications for Leronlimab
This study moves CCR5 out of the category of general "brain inflammation" and firmly establishes it as a direct regulator of cell survival and metabolic homeostasis.
Bypassing the Toxicity of Direct mTORC1 Inhibitors
For years, the pharmaceutical industry has tried to treat Alzheimer's by blocking mTORC1 directly using drugs like Rapamycin. However, direct blockade fails in human clinical trials because it introduces severe systemic toxicity and immune suppression. Prof. Rubinsztein’s team notes that targeting upstream metabolic nodes is a far superior therapeutic strategy.
Leronlimab acts as this precise upstream dial—safely modulating mTORC1 to restore autophagy without globally suppressing the patient's immune system".
..."The study highlights that canonical nutrient-sensing research has been historically flawed because it relied heavily on standard kidney cell lines (HEK293). In living brain tissue, the CCR5-inflammatory axis represents the true pathway of destruction"...
..." Leronlimab’s high-affinity monoclonal antibody structure allows it to lock down this distinct neuronal axis with an accuracy that standard small-molecule drugs cannot achieve"...
..."By shutting down the upstream chemokine assault, leronlimab releases the metabolic brakes inside the cell. The neuron can finally turn down its hyper-active mTORC1, restart its natural autophagy self-cleaning machinery, and actively clear out the toxic proteins driving the dementia.
..."This paper provides CytoDyn with the exact biological proof needed to design a highly focused Phase 2 Alzheimer’s protocol. It allows them to bypass vague inflammatory metrics and track restored autophagy and normalized mTORC1 biomarkers directly in patient cerebrospinal fluid (CSF)"...
2
